Tadas S. Vasaitis - Concepedia

Author

Tadas S. Vasaitis

University of Maryland, Baltimore

Also Known As

T. Sean Vasaitis, T. Vasaitis, Tadas S Vasaitis, Tadas S. Vasaitis, Tadas Sean Vasaitis, Tadas Vasaitis

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

University of Maryland, Baltimore University of Maryland Eastern Shore University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center Veterans Health Administration University of Coimbra

About

Tadas S. Vasaitis is an author at University of Maryland, Baltimore specializing in medicine, drug discovery, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	443
2	Health Sciences	2	2	70
3	Natural Sciences	2	2	186
4	Biochemistry	2	2	186
5	Biomolecular Engineering	1	1	29

Tadas S. Vasaitis

Publications

942

Citations

H-Index

Page 1

	Year	Citations
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens: Synthesis, in Vitro Biological Activity, Pharmacokinetics, and Antitumor Activity in the LAPC4 Human Prostate Cancer Xenograft Model Venkatesh Handratta, Tadas S. Vasaitis, Vincent C.O. Njar, Journal of Medicinal Chemistry	2005	246
Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1<i>H</i>-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer Tadas S. Vasaitis, Aashvini Belosay, Adam Schayowitz, Molecular Cancer Therapeutics	2008	134
Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone To Produce Novel Androgen Receptor Down-Regulating Agents as an Approach to Treatment of Advanced Prostate Cancer Puranik Purushottamachar, Abhijit M. Godbole, Lalji K. Gediya, Journal of Medicinal Chemistry Androgen ReceptorPharmacotherapyChemical BiologyPharmaceutical ChemistrySmall Molecules	2013	103
Three Dimensional Pharmacophore Modeling of Human CYP17 Inhibitors. Potential Agents for Prostate Cancer Therapy Omoshile Clement, C. M. Freeman, Rolf W. Hartmann, Journal of Medicinal Chemistry Hydrogen Bond AcceptorsDrug TargetBioorganic ChemistryPharmacotherapyChemical Biology	2003	83
Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): Head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model Robert D. Bruno, Tadas S. Vasaitis, Lalji K. Gediya, Steroids Stable AnalogsBiological EvaluationsMedicineAnti-tumor Efficacy EvaluationPharmacotherapy	2011	76
Mechanistic Relationship between Androgen Receptor Polyglutamine Tract Truncation and Androgen-dependent Transcriptional Hyperactivity in Prostate Cancer Cells Qianben Wang, T.S. Udayakumar, Tadas S. Vasaitis, Journal of Biological Chemistry	2004	49
Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors Vânia M. Moreira, Tadas S. Vasaitis, Vincent C.O. Njar, Steroids Medicinal ChemistryCyp17 InhibitorsMedicinePharmacotherapyDrug Development	2007	44
Evidence for Threshold Effects of 25-Hydroxyvitamin D on Glucose Tolerance and Insulin Resistance in Black and White Obese Postmenopausal Women John D. Sorkin, Tadas S. Vasaitis, Elizabeth A. Streeten, Journal of Nutrition ObesityNutritionInsulin ResistanceMetabolic SyndromeMetabolic Disorder	2014	43
Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent Puranik Purushottamachar, Aakanksha Khandelwal, Tadas S. Vasaitis, Bioorganic & Medicinal Chemistry UrologyMedicineHormonal ReceptorPharmacotherapyAnti-cancer Agent	2008	39
Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo Andrew K. Kwegyir‐Afful, Senthilmurugan Ramalingam, Vidya P. Ramamurthy, Cancers	2019	30

Page 1